Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort StudyThomas Benfield, Hanne Rolighed Christensen, Tomas Ø. Jensen et al.|Clinical Infectious Diseases|2021Cited by 93
Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasoneCæcilie Leding, Thomas Benfield, Jacob Bodilsen et al.|Scandinavian Journal of Infectious Diseases|2023Cited by 7
[Fulminant pneumococcal septicaemia in a patient with systemic lupus erythematosus and functional asplenia].Anne Troldborg, Merete Storgaard, Bent Deleuran|PubMed|2014Cited by 2
Correction to: Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort StudyThomas Benfield, Hanne Rolighed Christensen, Jacob Bodilsen et al.|Clinical Infectious Diseases|2022Cited by 2